On 1 April 2024, Alphastreet conducted an interview with Sagar Shah, Vice President, Sarthak Metals Pvt Ltd. In the interview, Mr. Shah
Insights from Sarthak Metals: Pioneering Steel & Biotech Ventures – An interview with the Vice President
Categories
Biotech
Shilpa Medicare Ltd Q3FY24; 9% rise in Revenue
Shilpa Medicare is engaged in the business of high quality Active Pharmaceuticals Ingredients (APIs), Intermediates, Formulations, New Drug delivery system, Peptides, Biotech
Rossari Biotech Ltd Q3FY24; 31% rise in Profits
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India. Financial Results: Rossari Biotech
Laurus Labs Limited Q3 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY24 Earnings Concall Business Performance Gross margins remained resilient at over 52% for several
Shilpa Medicare Ltd Q2FY24; 19% rise in Revenue
Shilpa Medicare is engaged in the business of high quality Active Pharmaceuticals Ingredients (APIs), Intermediates, Formulations, New Drug delivery system, Peptides, Biotech
Rossari Biotech Ltd Q2FY24; 38% rise in Profits
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India. Financial Results: Rossari Biotech
Laurus Labs Limited Q2 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY24 Earnings Concall Q2 FY24 Results Revenue declined 22% year-on-year to INR1,224 crores.. EBITDA
Laurus Labs Limited Q4 FY23 Earnings Conference Call Insights
https://youtu.be/5Vtl-XMN8qg Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Management Update: [00:09:24]LAURUSLABS said it invested in expanding non-ARV formulation
Rossari Biotech Ltd (ROSSARI) Q3 FY23 Earnings Concall Transcript
Rossari Biotech Ltd (NSE:ROSSARI) Q3 FY23 Earnings Concall dated Feb. 06, 2023. Corporate Participants: Aisha Shah -- Investor Relations Edward Menezes -- Executive Chairman and Co-Founder
Laurus Labs Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Management Update: [00:03:57] LAURUSLABS said its strong results were driven by
Laurus Labs Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/ZaM0EH45MvA Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Management Update: [00:10:45] LAURUSLABS said that on the R&D front,
Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Transcript
Laurus Labs Limited (NSE:LAURUSLABS) Q2 FY23 Earnings Concall dated Oct. 21, 2022 Corporate Participants: Satyanarayana Chava -- Chief Executive Officer V.V. Ravi Kumar -- Chief Financial Officer Analysts:
Laurus Labs Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/gMXrmnAGz9Y Key highlights from Laurus Labs Limited (LAURUSLABS) Q1 FY23 Earnings Concall Management Update: LAURUSLABS said it expects the US filing pace
Laurus Labs Limited Q4 FY22 Earnings Conference Call Insights
https://youtu.be/83rl6ffkU9c Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY22 Earnings Concall Management Update: LAURUSLABS said that based on its healthy product
Laurus Labs Limited Q3 FY22 Earnings Conference Call Insights
https://www.youtube.com/watch?v=Q_K9qU7RXvI Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY22 Earnings Concall Management Update: In 3Q, the company faced some interim challenges
Infographic: All you need to know about Dr Reddy’s Labs Q2 performance
Dr. Reddy's Laboratories(NSE:DRREDDY) recently reported its second-quarter 2022 earnings results. The company had a consolidated revenue of ₹5,992 crores with a growth